You are not currently logged in.
Access JSTOR through your library or other institution:
If You Use a Screen ReaderThis content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
One-Sided Sequential Stopping Boundaries for Clinical Trials: A Decision- Theoretic Approach
Donald A. Berry and Chih-Hsiang Ho
Vol. 44, No. 1 (Mar., 1988), pp. 219-227
Published by: International Biometric Society
Stable URL: http://www.jstor.org/stable/2531909
Page Count: 9
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Preview not available
We address one-sided stopping rules for clinical trials, or more generally, drug development programs, from a decision-theoretic point of view. If efficacy results are sufficiently negative then the trial will be stopped. But regardless of how positive the efficacy results are, the trial will continue in order to demonstrate safety. We show how sequential decisions should be made by a pharmaceutical company attempting to maximize its expected profits.
Biometrics © 1988 International Biometric Society